We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DCN Diagnostics and Asahi Kasei Fibers Launch Market Collaboration

By LabMedica International staff writers
Posted on 30 Jul 2013
Print article
DCN Diagnostics (Carlsbad, CA, USA) and Asahi Kasei Fibers Corp. (AKFC; Osaka, Japan) will collaborate on a new colored nanoparticle designed to increase sensitivity in rapid assays. The new partnership will be based around AKFC's patented high-performance cellulose nanobead product, NanoAct. NanoAct represents a major step forward in visual labels for use in lateral flow and other rapid assays.

Utilizing cellulose technology matured and advanced for more than 80 years, Asahi Kasei developed patented and innovative colored nanobeads, NanoAct. Using the multicolored nanobeads as labels for lateral flow immunoassays, increased sensitivity, and faster test time is expected. NanoAct also has dispersion stability and does not require surfactants for aggregation control.

Consisting of a range of high intensity colored beads NanoAct can be multiplexed, generate higher sensitivity, lower CV's, and improved stability over many existing visual labels such as colloidal gold. This enables the application of lateral flow assays in demanding field assays for emerging infectious disease, consumer applications, biothreat detection, and biomarker testing.

DCN is a supplier of assay development, training, and consulting services to lateral flow assay developers and manufacturers. The company will be AKFC's distribution partner in North America and will be their preferred provider of Original Equipment Manufacturer (OEM) services to NanoAct users worldwide, except Japan.

"This new product line is a great addition to DCN's existing portfolio of high performance reagents and materials for lateral flow test producers," said DCN's president, Brendan O'Farrell. "This new product line is a great addition to DCN's existing portfolio of high performance reagents and materials for lateral flow test producers."

DCN and AKFC will be showcasing NanoAct at the AACC conference in Houston, Texas (USA), on July 28–August 1, 2013.

Related Links:

DCN Diagnostics
Asahi Kasei Fibers Corp.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more